Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults

Abstract

IMPORTANCETrivalent adjuvanted inactivated influenza vaccine (aIIV3) and trivalent high-dose inactivated influenza vaccine (HD-IIV3) are US-licensed for adults aged 65 years and older. Data are needed on the comparative safety, reactogenicity, and health-related quality of life (HRQOL) effects of these vaccines. OBJECTIVE To compare safety, reactogenicity, and changes in HRQOL scores after aIIV3 vs HD-IIV3. DESIGN, SETTING, AND PARTICIPANTS This randomized blinded clinical trial was a multicenter US study conducted during the 2017 to 2018 and 2018 to 2019 influenza seasons. Among 778 community-dwelling adults aged at least 65 years and assessed for eligibility, 13 were ineligible and 8 withdrew before randomization. Statistical analysis was performed from August 2019 to August 2020. INTERVENTIONS Intramuscular administration of aIIV3 or HD-IIV3 after age-stratification (65-79 years; Ն80 years) and randomization. MAIN OUTCOMES AND MEASURESProportions of participants with moderate-to-severe injectionsite pain and 14 other solicited reactions during days 1 to 8, using a noninferiority test (5% noninferiority margin), and serious adverse events (SAE) and adverse events of clinical interest (AECI), including new-onset immune-mediated conditions, during days 1 to 43. Changes in HRQOL scores before and after vaccination (days 1, 3) were also compared between study groups.RESULTS A total of 757 adults were randomized, 378 to receive aIIV3 and 379 to receive HD-IIV3. Of these participants, there were 420 women (55%) and 589 White individuals (78%) with a median (range) age of 72 (65-97) years. The proportion reporting moderate-to-severe injection-site pain, limiting or preventing activity, after aIIV3 (12 participants [3.2%]) (primary outcome) was noninferior compared with HD-IIV3 (22 participants [5.8%]) (difference −2.7%; 95% CI, −5.8 to 0.4). Ten reactions met noninferiority criteria for aIIV3; 4 (moderate-to-severe injection-site tenderness, arthralgia, fatigue, malaise) did not. It was inconclusive whether these 4 reactions occurred in higher proportions of participants after aIIV3. No participant sought medical care for a vaccine reaction. No AECI was observed. Nine participants had at least SAE after aIIV3 (2.4%; 95% CI,1.1% to 4.5%); 3 had at least 1 SAE after HD-IIV3 (0.8%; 95% CI, 0.2% to 2.2%). No SAE was associated with vaccination.Changes in prevaccination and postvaccination HRQOL scores were not clinically meaningful and not different between the groups. (continued) Key Points Question What are the comparative safety, reactogenicity, and short-term effects of vaccination on health-related quality of life after trivalent adjuvanted inactivated influenza vaccine (aIIV3) or trivalent high-dose inactivated influenza vaccine (HD-IIV3) in adults aged 65 years and older? Findings In this randomized clinical trial of 757 older adults (378 receiving aIIV3 and 379 receiving HD-IIV3), the proportion of participants with moderate-to-severe injection-site pain (primary outcome) was not higher after aIIV3 than HD-IIV3. N...

Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study

“…We have demonstrated that most people in a UK population cohort receiving ChAdOx1 and BNT162b2 vaccines reported no AEs after vaccination. Indeed, reactogenicity-type symptoms are comparable to those associated with seasonal influenza vaccination 19. Furthermore, 43.7% of follow-up records submitted reported improved overall health and well-being after vaccination.…”

“…Indeed, reactogenicity-type symptoms are comparable to those associated with seasonal influenza vaccination. 19 Furthermore, 43.7% of follow-up records submitted reported improved overall health and well-being after vaccination.…”

“World in motion” – emulsion adjuvants rising to meet the pandemic challenges

“…The first licensure can be obtained by showing non-inferiority versus a “standard” vaccine; then, any data to show superiority, usually involving effectiveness, can be obtained during post-licensure studies. This approach has also been adopted by other manufacturers, such as Sanofi for their high-dose vaccine for older adults, with a relative efficacy trial performed post-licensure 37 , and Novavax, with their matrix-M adjuvanted vaccine 38 .…”

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season

“…One postlicensure randomized clinical trial in the United States evaluated the comparative safety of aIIV3 compared with HD-IIV3 in 757 adults aged ≥65 years (378 who received aIIV3 versus 379 who received HD-IIV3) ( 91 ). For the primary outcome, the proportion of participants who reported moderate to severe injection site pain that limited or prevented activity after aIIV3 (12 participants [3.2%]) was noninferior compared with the proportion reporting this outcome following HD-IIV3 (22 participants [5.8%]).…”